Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)

NCT ID: NCT03221634

Last Updated: 2019-03-25

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE2
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-08-01
• Study Completion Date: 2021-06-10

Brief Summary

The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) in combination with daratumumab in participants with relapsed refractory multiple myeloma (rrMM). The primary outcome measure for this study is the assessment of Objective Response Rate (ORR) in participants with rrMM.

Detailed Description

Study treatment will continue until the participant has completed 35 infusions (approximately 2 years) of pembrolizumab treatment. All participants who stop study treatment with stable disease (SD) or better may be eligible for up to an additional ~1 year of study treatment if they progress after stopping study treatment from the initial treatment phase.

Conditions

Multiple Myeloma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Pembrolizumab

Participants receive pembrolizumab 200 mg by intravenous (IV) infusion once every 3 weeks (Q3W) for up to 35 administrations (up to approximately 2 years) and receive daratumumab 16 mg/kg by IV infusion on Days 1, 8, 15, and 22 of Cycles 1-2; on Days 1 and 15 of Cycles 3-6, and on Day 1 of Cycle 7 and beyond, for up to 2 years. Each cycle is 28 days long.

Group Type: EXPERIMENTAL

Pembrolizumab

Intervention Type: BIOLOGICAL

IV infusion

Daratumumab

Intervention Type: BIOLOGICAL

IV infusion

Interventions

Pembrolizumab

IV infusion

Intervention Type: BIOLOGICAL

Daratumumab

IV infusion

Intervention Type: BIOLOGICAL

Other Intervention Names

MK-3475; DARZALEX®

Eligibility Criteria

Inclusion Criteria

• Has a confirmed diagnosis of active MM and measurable disease defined as: a.) Serum M-protein levels ≥0.5 g/dL or b.) Urine M-protein levels ≥200 mg/24 hours or c.) For participants without measurable serum and urine M-protein levels, an abnormal serum free light chain ratio (FLC κ/λ) with involved FLC level ≥100 mg/L.
• Has undergone prior treatment with ≥2 treatment lines of anti-myeloma therapy and must have failed their last line of treatment defined as lack of response or documented disease progression during or within 60 days of completing their last anti-myeloma therapy.
• Prior anti-myeloma treatments must have included an immunomodulatory drug (IMiD; i.e., lenalidomide, thalidomide, or pomalidomide) AND a proteasome inhibitor (PI; i.e., bortezomib, ixazomib, or carfilzomib) alone or in combination and participant must have failed therapy with an IMiD or PI or both.
• Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale.
• Has adequate organ function.
• Male participants must agree to use contraception during the treatment period and for at least 120 days after the last dose of study treatment and refrain from donating sperm during this period.
• Female participants must not be pregnant, breastfeeding, and must agree to use (or have their partner use) acceptable contraception during heterosexual activity during the treatment period and for at least 120 days after the last dose of study treatment.

Exclusion Criteria

• Has oligo-secretory myeloma, smoldering multiple myeloma (SMM), monoclonal gammopathy of undetermined significance (MGUS), Waldenström's macroglobulinemia, or any history of plasma cell leukemia.
• Has a history of repeated infections, primary amyloidosis, hyperviscosity, or polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome
• Has a known additional malignancy that is progressing or requires active treatment. Exceptions include early stage cancers (carcinoma in situ or Stage 1) treated with curative intent, basal cell carcinoma of the skin, squamous cell carcinoma of the skin, in situ cervical cancer, or in situ breast cancer that has undergone potentially curative therapy.
• Has known meningeal involvement of MM.
• Has severe hypersensitivity (≥ Grade 3) to pembrolizumab and/or daratumumab and any of its excipients.
• Has known allergies, hypersensitivity, or intolerance to monoclonal antibodies (mAbs) or human proteins, or their excipients, or known sensitivity to mammalian-derived products.
• Has an active autoimmune disease that has required systemic treatment in past 2 years.
• Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.
• Has either of the following: a.) Known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) <50% of predicted normal, or b.) Known moderate or severe persistent asthma within the past 2 years, or uncontrolled asthma of any classification.
• Has an active infection requiring systemic therapy.
• Has a known history of human immunodeficiency virus (HIV) infection.
• Has a known history of hepatitis B or known active hepatitis C.
• Has a known history of active tuberculosis (TB).
• Has received prior solid organ transplant.
• Has clinically significant cardiac disease or electrocardiogram (ECG) abnormalities or any history of clinically significant ventricular arrhythmias.
• Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study treatment.
• Has previously received daratumumab or other anti-cluster of differentiation 38 (anti-CD38) therapies.
• Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another co-inhibitory T-cell receptor (i.e., cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], OX-40, CD137) or has previously participated in a Merck pembrolizumab (MK-3475) clinical study.
• Has received prior anti-myeloma therapy including but not limited to dexamethasone, IMiDs, PIs, monoclonal antibody, chemotherapy, or radiation therapy within 4 weeks or 5 half-lives (whichever is longer) before first dose of study treatment or not recovered (≤ Grade 1 or at Baseline) from AEs due to previously administered agents.
• Has undergone prior allogeneic stem cell transplant (allo-SCT) within the last 5 years.
• Has received autologous stem cell transplant (auto-SCT) within 12 weeks before the first dose of study treatment or are planning for or are eligible for auto- or allo-SCT.
• Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study treatment.
• Has received prior radiotherapy within 2 weeks of start of study treatment. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-central nervous system (CNS) disease.
• Has received a live vaccine within 30 days prior to the first dose of study treatment.
• Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Merck Sharp & Dohme LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Medical Director

Role: STUDY_DIRECTOR

Merck Sharp & Dohme LLC

Locations

Mayo Clinic Jacksonville ( Site 0003)

Jacksonville, Florida, United States

Emory University School of Medicine ( Site 0002)

Atlanta, Georgia, United States

Karmanos Cancer Institute ( Site 0001)

Bloomfield Hills, Michigan, United States

Calgary Lab Services - Foothills Medical Centre ( Site 0105)

Calgary, Alberta, Canada

Cross Cancer Institute ( Site 0104)

Edmonton, Alberta, Canada

Capital Health Queen Elizabeth II Health Sciences Centre ( Site 0101)

Halifax, Nova Scotia, Canada

Hopital Maisonneuve-Rosemont [Montreal, Canada] ( Site 0102)

Montreal, Quebec, Canada

McGill University Health Centre ( Site 0100)

Montreal, Quebec, Canada

CHU de Quebec - Hopital de l'Enfant-Jesus ( Site 0106)

Québec, Quebec, Canada

CHRU Lille Hospital Claude Huriez ( Site 0200)

Lille, , France

Hopital Saint-Louis ( Site 0202)

Paris, , France

Centre Hopitalier Lyon Sud ( Site 0201)

Pierre-Bénite, , France

Rambam Medical Center ( Site 0700)

Haifa, , Israel

Rabin Medical Center ( Site 0702)

Petah Tikva, , Israel

Sourasky Medical Center ( Site 0701)

Tel Aviv, , Israel

Sheba MC ( Site 0703)

Tel Litwinsky, , Israel

Hospital Universitari Germans Trias i Pujol ( Site 0302)

Badalona, , Spain

Instituto Catalan de Oncologia ICO - Hospital Duran i Reynals ( Site 0303)

L'Hospitalet de Llobregat, , Spain

Clinica Universitaria de Navarra ( Site 0301)

Pamplona, , Spain

Hospital Clinico Universitario de Salamanca ( Site 0300)

Salamanca, , Spain

Hospital Clinico Universitario de Valencia ( Site 0304)

Valencia, , Spain

Skaenes Universitetssjukhus Lund ( Site 0500)

Lund, , Sweden

Karolinska Universitetssjukhuset ( Site 0501)

Stockholm, , Sweden

Countries

United States; Canada; France; Israel; Spain; Sweden

Other Identifiers

2017-001001-32

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

3475-668

Identifier Type: -

Identifier Source: org_study_id